Streetbeat News

HLVX

HilleVax, Inc.

https://www.hillevax.com

Industry

Biotechnology

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Open

1.77

Mkt cap

87M

Volume

75K

High

1.78

P/E Ratio

-0.57

52-wk high

18.00

Low

1.74

Div yield

N/A

52-wk low

1.55

Shares of Applied DNA Sciences (APDN) fell sharply by 67.5% after announcing a $12 million public offering. Other notable stock movements include Sharps Technology (STSS) climbing 207%, Insmed Incorporated (INSM) jumping 110% on positive Phase 3 study results, and Pineapple Energy (PEGY) gaining 91.5% after a subsidiary signed a significant project. Several other stocks experienced significant gains and losses during Tuesday's mid-day session.

Portfolio Pulse from Avi Kapoor

May 28, 2024 | 5:24 pm

JP Morgan analyst Eric Joseph maintains an Overweight rating on HilleVax (NASDAQ:HLVX) and raises the price target from $21 to $24.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 5:22 pm

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on HilleVax (NASDAQ:HLVX) with a maintained price target of $28.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 12:34 pm

HilleVax (NASDAQ:HLVX) reported Q1 2024 adjusted EPS losses of $(0.97), missing the consensus estimate of $(0.84) by 15.48%.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:10 pm

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on HilleVax (NASDAQ:HLVX) and maintained a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:27 am

HilleVax (NASDAQ:HLVX) reported Q4 earnings, beating estimates with an EPS of $-0.78 against an expected $-0.83, a 6.0% beat. However, revenue remained unchanged from the previous year. Following a similar earnings beat last quarter, HLVX's share price increased by 6.0% the next day.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:30 pm

HilleVax reported a Q4 2023 GAAP EPS of $(0.78), surpassing the analyst consensus estimate of $(0.83) by 6.02%.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 8:16 pm

HilleVax and Kangh have entered into an exclusive license agreement for the development and commercialization of a hexavalent VLP norovirus vaccine candidate outside of China. This partnership could potentially enhance HilleVax's product pipeline and market reach, while providing Kangh with licensing revenues and a share in the global market, excluding China.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:13 pm

HC Wainwright & Co. analyst Matthew Caufield has initiated coverage on HilleVax (NASDAQ:HLVX) with a Buy rating and set a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:25 am

Guggenheim analyst Seamus Fernandez has maintained a Buy rating on HilleVax (NASDAQ:HLVX) but reduced the price target from $38 to $34.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 7:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.